Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance-Reference-Cited by-同舟云学术

Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance

Published:2001-10 Issue:2 Volume:28 Page:105-113
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes

Author:

Cohen Stuart James W. T.,Wensing Annemarie M. J.,Kovacs Colin,Righart Maike,de Jong Dorien,Kaye Steve,Schuurman Rob,Visser Corjan J. T.,Boucher Charles A. B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference33 articles.

1. Human Immunodeficiency Virus Replication and Genotypic Resistance in Blood and Lymph Nodes after a Year of Potent Antiretroviral Therapy

2. Activation and Cell Cycle Antigens in CD4+and CD8+T Cells Correlate with Plasma Human Immunodeficiency Virus (HIV‐1) RNA Level in HIV‐1 Infection

3. Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary Study

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study;Journal of Medical Virology;2023-10

2. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium;HIV Medicine;2023-04-10

3. Transient Viral Rebound in Children with Perinatally Acquired HIV-1 Induces a Unique Soluble Immunometabolic Signature Associated with Decreased CD4/CD8 Ratio;Journal of the Pediatric Infectious Diseases Society;2023-02-02

4. HIV-1 Genotypic Resistance Testing Using Sanger and Next-Generation Sequencing in Adults with Low-Level Viremia in China;Infection and Drug Resistance;2022-11

5. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium;HIV Medicine;2022-08-08